<DOC>
	<DOC>NCT00002069</DOC>
	<brief_summary>To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.</brief_summary>
	<brief_title>A Study of DTC in Patients With AIDS and AIDS Related Complex</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Ditiocarb</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication: Allowed: Zidovudine (AZT). Exclusion Criteria Coexisting Condition: Patients with the following are excluded: Active opportunistic infection or progressive Kaposi's sarcoma (KS). Dementia. Lymphoma. Concurrent Medication: Excluded within 3 weeks of study entry: Other experimental AIDS therapy. Patients with the following are excluded: Active opportunistic infection or progressive Kaposi's sarcoma (KS). Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1989</verification_date>
	<keyword>Ditiocarb</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>